OctoCells

Octocells is a French biotechnology company based in Rouen that develops advanced three-dimensional (3D) cell culture solutions for bioproduction and research. Their core offering, the CellSpace HA platform, utilizes a patented, animal-free hyaluronic acid-based bioscaffold. This technology is designed to address limitations in traditional 2D culture and animal-derived matrices by providing a highly scalable, standardized, and reproducible environment for cell growth. The system supports a variety of applications, including oncology, cell therapies, vaccine production, regenerative medicine, and cultivated proteins. By combining expertise in biomaterials with digital technologies—such as the potential use of digital twins for bioreactor simulation—the company aims to optimize production processes, reduce costs, and improve overall bioproduction efficiency.

The company's solutions are intended to assist researchers and industrial partners in scaling production while maintaining ethical standards and consistent biological results. The CellSpace HA system is compatible with standard lab formats and allows for adjustable stiffness, facilitating high-density cell growth and extended culture durations. Through these innovations, Octocells addresses critical industry barriers related to reproducibility and the ethical impact of production. The company was founded in 2022 by Zied Souguir and Grégory Maubon, and it maintains strategic partnerships and membership in biotechnology incubators to accelerate the transition of its technologies from research settings to industrial and clinical applications.